- Home
- KRP vs OCUL Comparison
KRP vs OCUL Comparison
Compare KRP & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- OCUL
- Stock Information
- Founded
- KRP 2013
- OCUL 2006
- Country
- KRP United States
- OCUL United States
- Employees
- KRP N/A
- OCUL N/A
- Industry
- KRP Oil & Gas Production
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- OCUL Health Care
- Exchange
- KRP Nasdaq
- OCUL Nasdaq
- Market Cap
- KRP 1.1B
- OCUL 957.3M
- IPO Year
- KRP 2017
- OCUL 2014
- Fundamental
- Price
- KRP $13.43
- OCUL $9.02
- Analyst Decision
- KRP Hold
- OCUL Strong Buy
- Analyst Count
- KRP 5
- OCUL 10
- Target Price
- KRP $17.40
- OCUL $16.11
- AVG Volume (30 Days)
- KRP 602.2K
- OCUL 1.8M
- Earning Date
- KRP 07-31-2025
- OCUL 05-05-2025
- Dividend Yield
- KRP 12.65%
- OCUL N/A
- EPS Growth
- KRP N/A
- OCUL N/A
- EPS
- KRP 0.07
- OCUL N/A
- Revenue
- KRP $312,876,555.00
- OCUL $59,647,000.00
- Revenue This Year
- KRP $10.45
- OCUL N/A
- Revenue Next Year
- KRP $3.27
- OCUL $20.05
- P/E Ratio
- KRP $185.11
- OCUL N/A
- Revenue Growth
- KRP 3.03
- OCUL N/A
- 52 Week Low
- KRP $10.98
- OCUL $4.79
- 52 Week High
- KRP $17.07
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- KRP 56.70
- OCUL 67.24
- Support Level
- KRP $13.01
- OCUL $6.86
- Resistance Level
- KRP $13.43
- OCUL $8.63
- Average True Range (ATR)
- KRP 0.24
- OCUL 0.50
- MACD
- KRP -0.00
- OCUL 0.15
- Stochastic Oscillator
- KRP 84.08
- OCUL 99.31
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.